RxDoctor Payments Data

Carolyn Ringhoffer, MD

Gynecology · Mobile, ALNPI 1093736332

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $205 of the $256 with a category attached, or 80.0%. It is spread thinly across 9 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for gynecology clinicians in AL, where the typical reported total is $276.

$256in general payments, 2019–2025

Across 12 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$58
  • Avion Pharmaceuticals$50
  • Sumitomo Pharma America, Inc.$40
  • Organon$25
  • Exeltis, USA Inc.$19
  • Shield Therapeutics Inc$18
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$20580%
  • Education$3313%
  • Gifts$187%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)3$58
Avion Pharmaceuticals1$50
Sumitomo Pharma America, Inc.2$40
Organon1$25
Exeltis, USA Inc.1$19
Shield Therapeutics Inc1$18
Ascend Therapeutics US, LLC1$18
Bayer1$14
Amgen1$14

How this compares

$256 in reported general payments places this provider in the 45th percentile of 51 gynecology providers in Alabama.

See all gynecology providers in Alabama

Medicare billing

Part B allowed, 2024
$15,250
Medicare patients
107
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab33$57,234
MyrbetriqMirabegron48$49,828
PremarinEstrogens, Conjugated21$11,619
Estradiol287$9,465
Raloxifene Hcl96$8,352
ValacyclovirValacyclovir Hcl28$1,976
Solifenacin Succinate35$1,273
Oxybutynin Chloride ErOxybutynin Chloride46$957
NitrofurantoinNitrofurantoin Macrocrystal17$854
Alendronate Sodium91$826
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet14$723
Oxybutynin Chloride43$641
Medroxyprogesterone Acetate36$484
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$298
Metronidazole11$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$14$57,23433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 51 gynecology providers in Alabama.

Other gynecology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →